• Med BioGene Inc., of Vancouver, British Columbia, entered a nonbrokered private placement of a minimum of $1.3 million and a maximum of $1.6 million of units with Berkeley Capital Corp. II. Each unit will be price at 8 cents and will consist of one common share and one-half of one common share purchase warrant. Each whole common share warrant will entitle the holder to purchase one common share at 10 cents each for a period of 24 months. MBI will use the proceeds for the development and commercialization of LungExpress Dx and for general corporate purposes.

• Pharmos Corp., of Iselin, N.J., completed a private placement of 18 million shares of common stock and warrants for an aggregate purchase price of $1.8 million. The exercise price of the warrants, which have a five-year term, is 12 cents per share. The three purchasers were two existing investors, Venrock Associates and New Enterprise Associates and a trust affiliated with Robert F. Johnston, executive chairman. Proceeds will be used to fund completion of the ongoing Dextofisopam Phase IIb trial and company operations through the end of the year.